Overview

Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors

Status:
Unknown status
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The investigators plan to improve event free survival rate and reduce treatment related toxicities of pediatric patients with high risk/recurrent CNS tumors by administrating tandem high dose chemotherapy and autologous stem cell rescue.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Carboplatin
Etoposide
Etoposide phosphate
Melphalan
Thiotepa
Topotecan